Compare SGU & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGU | IMRX |
|---|---|---|
| Founded | 1995 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.0M | 340.7M |
| IPO Year | 1997 | 2021 |
| Metric | SGU | IMRX |
|---|---|---|
| Price | $12.86 | $5.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.20 |
| AVG Volume (30 Days) | 22.3K | ★ 737.9K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.90% | N/A |
| EPS Growth | N/A | ★ 37.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,784,418,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.70 | ★ N/A |
| Revenue Growth | ★ 1.04 | N/A |
| 52 Week Low | $11.31 | $1.40 |
| 52 Week High | $13.53 | $10.08 |
| Indicator | SGU | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.63 | 50.04 |
| Support Level | $12.31 | $5.31 |
| Resistance Level | $12.99 | $5.80 |
| Average True Range (ATR) | 0.34 | 0.31 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 39.84 | 28.99 |
Star Group LP is a home heating oil and propane distributor and services provider with one reportable operating segment that principally provides heating related services to residential and commercial customers. It serves residential and commercial customers whose primary use is to heat their homes and buildings in the Northeast and Mid-Atlantic U.S. regions. The company derives the majority of revenue from Petroleum products, which consist of home heating oil and propane as well as diesel fuel and gasoline.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.